Atopic keratoconjunctivitis – Diagnostics – Overview of Information and Clinical Research

Diagnosing atopic keratoconjunctivitis requires careful attention to symptoms and a thorough examination by an eye care specialist. This chronic inflammatory condition affects both the surface of the eye and the eyelids, and recognizing it early can help prevent serious complications that may impact vision.

Introduction: When to Seek Diagnostic Evaluation

If you experience persistent itching in your eyes, especially if you also have a history of skin eczema, asthma, or other allergic conditions, it is important to consider an evaluation for atopic keratoconjunctivitis. This condition does not appear suddenly but develops over time, typically becoming noticeable between the late teenage years and middle age.^[1] The majority of people who develop this eye problem already have atopic dermatitis—a type of eczema that causes dry, itchy, and inflamed skin—present in about ninety-five percent of cases.^[1]

You should seek diagnostic testing if you notice ongoing eye discomfort that doesn’t go away with simple remedies, or if your symptoms interfere with daily activities. The primary warning sign is intense itching of the eyes that persists throughout the year, unlike seasonal allergies which come and go with pollen seasons.^[1] Other symptoms that warrant medical attention include mucus-like discharge from the eyes, excessive tearing, changes in the appearance of your eyelids such as thickening or crusting, or any changes in your vision.^[2]

People with a family history of allergic conditions, including hay fever, asthma, or food allergies, face a higher risk of developing atopic keratoconjunctivitis.^[1] Males are more commonly affected than females.^[2] If you already manage atopic dermatitis, regular eye examinations become particularly important because eye complications can develop quickly, even if you haven’t noticed eye symptoms yet.^[16]

⚠️ Important

Atopic keratoconjunctivitis can lead to potentially blinding complications if left untreated. The disease tends to worsen over time when not properly managed, with the cornea—the clear front surface of your eye—becoming progressively more damaged. Early diagnosis and consistent treatment are essential to preserve your vision and quality of life.

The condition affects both eyes simultaneously and follows a pattern of flare-ups and periods of relative calm, though unlike some seasonal eye allergies, it continues throughout the year.^[1] Some patients report that their symptoms become worse during winter months.^[5] Because the disease is chronic and potentially progressive, anyone with persistent eye symptoms and a history of allergic conditions should not delay seeking professional evaluation.

Classic Diagnostic Methods

The diagnosis of atopic keratoconjunctivitis begins with your doctor gathering detailed information about your medical history. Your physician will specifically ask whether you have atopic dermatitis, asthma, or other allergic conditions, as these significantly increase the likelihood of developing eye involvement.^[5] A family history of similar conditions also provides important diagnostic clues. The doctor will want to know about the nature of your eye symptoms—when they started, how severe they are, what makes them better or worse, and whether they occur throughout the year or only at certain times.

The physical examination of your eyes and eyelids forms the cornerstone of diagnosis. Using a specialized microscope called a slit lamp, the eye care professional can examine different structures of your eye in magnified detail.^[1] During this examination, the doctor looks for characteristic signs that distinguish atopic keratoconjunctivitis from other eye conditions. The eyelids often show distinctive changes including thickening, darkening of the skin color, redness, and crusting.^[1] A condition called madarosis—loss of eyelashes—may be present, particularly along the lower eyelid, and the lid margin can appear rolled and scarred.

The examination also focuses on the conjunctiva, which is the clear tissue covering the white part of your eye and the inside of your eyelids. In atopic keratoconjunctivitis, this tissue becomes inflamed and may show tiny bumps called micropapillae, primarily on the tarsal conjunctiva of the lower eyelid.^[1] More severe cases can develop symblepharon, a condition where the conjunctiva forms adhesions or bands of scar tissue, and fornix foreshortening, where the natural pocket between the eyelid and eyeball becomes shallower due to scarring.^[1]

The cornea—the clear window at the front of your eye—often shows significant changes that help confirm the diagnosis. The doctor looks for a growth of blood vessels into the normally clear cornea, a condition called neovascularization, as well as clouding or scarring. A particularly concerning finding is conjunctivalization of the cornea, where tissue that normally belongs only on the conjunctiva grows over the cornea, sometimes extending into the visual axis and affecting vision.^[1] The peripheral parts of the cornea may show white or yellowish deposits from lipid buildup, known as lipid keratopathy.

Your doctor will also examine the lens inside your eye. People with atopic keratoconjunctivitis have a higher tendency to develop cataracts, particularly a type called posterior subcapsular cataract, which forms at the back of the lens.^[1] This type of cataract can develop earlier in life than typical age-related cataracts and may progress more rapidly. The examination includes measuring your eye pressure because some patients with this condition are at increased risk for developing elevated pressure or glaucoma.

Because atopic keratoconjunctivitis shares symptoms with several other eye conditions, doctors must carefully distinguish it from similar disorders. The differential diagnosis includes conditions like vernal keratoconjunctivitis, which typically affects younger patients and follows a seasonal pattern; seasonal or year-round allergic conjunctivitis without corneal involvement; giant papillary conjunctivitis, often associated with contact lens wear; and various forms of infectious conjunctivitis.^[5] The presence of eczema around the eyes and the characteristic pattern of both eyelid and corneal changes help distinguish atopic keratoconjunctivitis from these other conditions.

In some cases, additional testing may help confirm the diagnosis or rule out other conditions. A blood test measuring serum IgE levels can indicate the presence of an atopic condition, though it cannot specifically diagnose atopic keratoconjunctivitis by itself.^[16] The test measures immunoglobulin E, an antibody that the immune system produces in excessive amounts in people with atopic conditions. While elevated IgE supports the diagnosis in someone with compatible eye findings, normal levels don’t rule out the condition.

When the diagnosis remains uncertain, more specialized testing might be performed. Brush cytology involves taking a sample from the inside surface of the eyelid using a small brush, similar to a mascara wand, to examine the types and numbers of inflammatory cells present.^[16] Another advanced technique called confocal scanning laser microscopy can visualize inflammatory cells in the eye tissues without removing tissue samples, making it less invasive than brush cytology.^[16] However, these specialized tests are not routinely needed for diagnosis in most cases, as the clinical examination and medical history typically provide sufficient information.

Diagnostics for Clinical Trial Qualification

Currently, there are no established standardized diagnostic protocols specifically designed for enrolling patients in clinical trials for atopic keratoconjunctivitis. Research on treatment options for this condition, particularly studies focusing on systemic medications, remains limited. A comprehensive review of clinical trials found no randomized controlled trials that met inclusion criteria for evaluating systemic treatments in children and young people with atopic keratoconjunctivitis.^[7] This absence of trials highlights a significant gap in our understanding of the best treatment approaches, especially for younger patients.

When clinical trials do occur for this condition, researchers typically use the same diagnostic methods employed in routine clinical practice to identify and enroll suitable participants. These would include confirmation of the diagnosis through medical history, documentation of atopic conditions such as eczema or asthma, and comprehensive eye examination findings using slit lamp microscopy. The severity of the disease would need to be assessed and documented to ensure that enrolled patients meet the study’s inclusion criteria regarding disease stage or extent.

For trials testing new medications or treatment approaches, researchers would likely establish specific entry criteria based on objective measurements. These might include the degree of corneal involvement, the presence or absence of complications such as corneal ulcers or scarring, visual acuity measurements, and assessment of inflammatory markers in the eye. Some trials might require documentation of failed previous treatments or specify that patients have disease severe enough to warrant experimental interventions but not so advanced that treatment would be unlikely to help.

The lack of validated outcome measures specifically designed for atopic keratoconjunctivitis presents another challenge for clinical trials. Researchers note the need to develop measures that can capture both objective clinical improvements and patient-reported outcomes that reflect how the condition and its treatment affect daily life.^[7] Future clinical trials would benefit from standardized grading systems to assess disease severity, validated questionnaires to measure symptoms and quality of life, and agreed-upon definitions of what constitutes treatment success or failure.

⚠️ Important

The absence of clinical trials for systemic treatments in atopic keratoconjunctivitis means that treatment decisions often rely on clinical experience and case reports rather than high-quality evidence from randomized studies. Patients interested in participating in research should discuss options with their eye care providers and consider checking clinical trial registries for any new studies that may be recruiting participants.

Prognosis and Survival Rate

Prognosis

The outlook for people with atopic keratoconjunctivitis depends significantly on how early the condition is recognized and how consistently it is treated. The disease follows a chronic course with periods of worsening and improvement, continuing throughout adult life.^[1] Unlike some allergic eye conditions that resolve with age, atopic keratoconjunctivitis typically persists as a long-term condition requiring ongoing management.

When treatment is started early and followed consistently, many patients can maintain good vision and comfortable eyes. However, the condition can progress rapidly when left untreated or when patients discontinue their medications. A documented case showed that a patient who stopped treatment experienced significant disease progression over just two years, with the conjunctival tissue growing over the cornea into the visual axis and substantial decrease in visual clarity.^[1] This example illustrates how critical continuous treatment is for preserving vision.

Several factors influence the long-term outlook. The severity of the underlying atopic dermatitis often correlates with the severity of eye involvement—patients with poorly controlled skin eczema tend to have more aggressive eye disease.^[1] Younger patients who develop the condition may face more years of disease activity and accumulate more damage over time. The development of complications such as corneal scarring, ulceration, or significant conjunctival scarring with symblepharon worsens the prognosis for maintaining good vision.

Progressive corneal changes represent one of the most concerning aspects of the disease. As blood vessels grow into the normally clear cornea and scar tissue forms, vision becomes increasingly compromised. In severe cases, the cornea can become so clouded that corneal transplantation might be considered, though managing atopic keratoconjunctivitis after transplant presents its own challenges. The chronic inflammation can also lead to chronic pain and discomfort that significantly affects quality of life, even when vision remains relatively preserved.

Another important factor in prognosis is the increased risk of developing cataracts. People with atopic keratoconjunctivitis develop cataracts more frequently and at younger ages than the general population.^[1] While cataract surgery can restore vision lost to lens clouding, the presence of active inflammation and corneal disease can complicate surgery and recovery. Additionally, some patients may develop elevated eye pressure or glaucoma, which requires its own monitoring and treatment to prevent further vision loss.

The prognosis improves substantially with a multidisciplinary approach to care. When eye specialists work together with dermatologists to control the underlying skin disease, and with allergists to manage other allergic conditions, patients typically experience better outcomes. Avoiding environmental triggers, using prescribed medications consistently, and attending regular follow-up appointments all contribute to a more favorable long-term outlook. Patients who actively participate in their care and understand the chronic nature of their condition generally do better than those who seek treatment only during severe flare-ups.

Survival rate

Atopic keratoconjunctivitis is not a life-threatening condition, and discussions of survival rates are not applicable to this disease. However, the condition can be potentially blinding if severe and untreated. The term “sight-threatening” is used in medical literature to describe the serious nature of this eye disease.^[2] While the condition itself does not cause death, it can lead to permanent vision loss through various mechanisms including corneal scarring, ulceration, and the development of complications that affect the cornea’s clarity.

The risk of severe vision loss increases with disease duration and severity. Progressive corneal conjunctivalization, where abnormal tissue grows over the clear cornea, can advance to the point where it blocks the visual axis—the central clear path that light must travel through to reach the retina at the back of the eye. Once significant scarring has occurred, restoring clear vision becomes challenging even with surgical intervention. Therefore, while survival is not at issue, preservation of functional vision represents the critical outcome that medical care aims to protect.

Quality of life can be significantly impaired by this condition even when vision is maintained. The chronic itching, burning, and discomfort can interfere with work, school, social activities, and sleep. The visible changes to the eyelids and eyes may affect self-image and confidence. The need for ongoing medical care, frequent medication use, and regular monitoring visits also impacts daily life. These factors underscore why early recognition and consistent management matter so much, even though the disease does not threaten life itself.

#1 Clinical Trials Search in Europe